Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Hims & Hers believes that is where the controversy lies. “We called on the industry and said that they need to change — and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The body does not absorb berberine well, limiting its ability to affect body weight significantly. However, berberine may ...

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...

The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

New obesity management medications, including glucagon-like peptide 1 receptor agonists (GLP-1RAs), have shown high efficacy in clinical trials. Among GLP-1RAs, liraglutide and semaglutide have ...